MAGEA3 and prostate carcinoma: Reinduction of cancer germline antigens through reversion of genetic repression marks is also feasible in many solid cancers, e.g. in esophageal squamous cell carcinoma for MAGE-A3 (57), ovarian cancer for protein expressed in prostate, ovary, testis and placenta (POTE) genes (58), mesothelioma for NY-ESO-1, MAGE-A1, MAGE-A3, and XAGE-1b (59) and prostate cancer for NY-ESO-1 (60).